Equities

Edap Tms SA

Edap Tms SA

Actions
Health CareMedical Equipment and Services
  • Price (USD)7.14
  • Today's Change-0.20 / -2.72%
  • Shares traded30.48k
  • 1 Year change-37.64%
  • Beta0.4722
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners

  • Revenue in USD (TTM)65.00m
  • Net income in USD-22.78m
  • Incorporated1979
  • Employees307.00
  • Location
    Edap Tms SAParc ActiviteLa Poudrette Lamartine4/6 Rue du DauphineVAULX-EN-VELIN 69120FranceFRA
  • Phone+33 472153150
  • Fax+33 472153151
  • Websitehttps://www.edap-tms.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Orchestra Biomed Holdings Inc2.76m-49.12m182.46m56.00--2.68--66.11-1.49-1.490.08321.900.02890.881528.3149,285.71-51.49---61.01--93.26---1,779.71--7.94--0.00---21.88---37.91------
Semler Scientific Inc68.18m20.58m189.84m92.0010.282.598.962.782.632.638.7110.430.968815.2813.62741,130.4029.2538.8332.2444.4189.7690.2230.1932.5810.56--0.00--20.2825.9843.6932.64-0.3821--
Stereotaxis Inc26.77m-22.06m192.18m122.00--11.59--7.18-0.2737-0.27370.33180.27080.56171.466.01219,434.40-43.46-25.02-61.11-34.1255.5167.57-77.37-41.901.88--0.00---4.89-1.82-12.33--6.63--
Butterfly Network Inc65.90m-133.70m198.76m225.00--0.8901--3.02-0.6507-0.65070.32091.060.18260.73764.69292,888.90-37.04---42.70--25.58---202.88--3.57--0.00---10.21--20.76------
CVRx Inc42.09m-52.01m199.11m200.00--3.00--4.73-2.48-2.482.013.070.36780.67815.64210,430.00-45.45---48.95--84.45---123.58--10.87-21.110.3064--74.89--0.5528------
Akoya Biosciences Inc96.63m-63.32m199.34m330.00--3.69--2.06-1.48-1.482.181.090.54232.497.23292,827.30-35.53---44.59--58.27---65.53--2.94-10.940.5882--29.09--10.36------
Utah Medical Products, Inc.50.22m16.64m243.77m169.0014.851.9210.624.854.574.5713.8135.350.38732.1911.25297,183.4012.8312.6913.3813.1959.8161.5733.1230.5120.53--0.0037.05-3.933.640.98341.659.711.86
AngioDynamics, Inc.324.01m-192.37m251.14m815.00--1.16--0.7751-4.78-4.788.105.410.74682.666.46397,555.80-44.34-9.12-54.02-10.1750.1754.23-59.37-19.481.62--0.00--7.135.30-97.54--3.55--
AxoGen Inc159.01m-21.72m253.05m426.00--2.61--1.59-0.5070-0.50703.712.220.81081.636.72373,267.60-11.07-13.92-12.85-15.8478.4679.74-13.66-20.282.14--0.3277--14.7413.6324.98--17.70--
Edap Tms SA (ADR)65.00m-22.78m264.92m307.00--4.33--4.08-0.616-0.6161.761.650.62722.683.86211,736.50-21.98-6.62-29.54-9.2240.4043.23-35.05-9.592.30-27.440.1045--9.649.05-622.06--32.75--
Senseonics Holdings Inc22.39m-60.39m268.01m132.00--7.48--11.97-0.1023-0.10230.03870.13850.14182.406.41169,621.20-38.24-73.65-45.21-106.9713.81-40.41-269.73-649.867.03--0.3593--36.623.43-142.49---18.76--
Sight Sciences Inc81.06m-55.55m296.49m214.00--2.44--3.66-1.14-1.141.672.450.42691.705.51378,761.70-29.26-38.78-31.77-42.2085.3480.74-68.53-105.1412.65-10.590.2201--13.6360.8435.59--6.77--
Bioventus Inc502.76m-122.57m316.07m970.00--1.76--0.6287-1.97-2.938.062.250.45522.144.10448,889.30-14.34---18.91--62.8770.26-31.51-9.180.94430.37310.6354--18.8511.89-919.12------
Tactile Systems Technology Inc274.42m28.52m339.17m992.0012.021.749.681.241.191.1911.908.201.026.025.60276,636.1010.630.901513.231.0949.9549.1010.390.83092.99--0.13080.0011.2013.81259.6033.91-23.62--
Zynex Inc188.68m8.17m351.23m1.10k48.6510.7627.771.860.22610.22615.391.021.592.526.56171,530.006.8914.588.4117.5280.2279.624.3310.442.877.240.6381--16.5442.01-42.910.37412.19--
Data as of May 03 2024. Currency figures normalised to Edap Tms SA's reporting currency: US Dollar USD

Institutional shareholders

41.86%Per cent of shares held by top holders
HolderShares% Held
Soleus Capital Management LP (Investment Management)as of 31 Dec 20237.23m19.57%
Morgan Stanley & Co. International Plcas of 31 Dec 20233.38m9.15%
Rock Springs Capital Management LPas of 31 Dec 20231.39m3.75%
Archon Capital Management LLCas of 31 Dec 20231.21m3.27%
Federated Global Investment Management Corp.as of 31 Dec 2023880.87k2.39%
Bruce & Co., Inc.as of 31 Dec 2023553.65k1.50%
Apis Capital Advisors LLCas of 31 Dec 2023536.10k1.45%
Cahill Financial Advisors, Inc.as of 31 Dec 2023134.96k0.37%
Cetera Advisor Networks LLCas of 31 Dec 202376.16k0.21%
Orion Capital Management LLC (CA)as of 31 Dec 202375.57k0.21%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.